TREGenerationProject ID: 643776
Finanziato nell'ambito di:
Repair of tissue and organ damage in refractory chronic graft versus host disease after hematopoietic stem cell transplantation by the infusion of purified allogeneic donor regulatory T lymphocytes
Dettagli del progetto
Costo totale:EUR 5 899 250
Contributo UE:EUR 5 899 250
Argomento (i):PHC-15-2014 - Clinical research on regenerative medicine
Invito a presentare proposte:H2020-PHC-2014-single-stageSee other projects for this call
Meccanismo di finanziamento:RIA - Research and Innovation action
Our proposal encompasses parallel clinical trials addressing the feasibility and the effectiveness of donor-derived regulatory T cells (Treg) as a therapeutic agent in the treatment and prevention of tissue and organ damage resulting from graft versus host disease (GVHD) after hematopoietic stem cell transplantation (HSCT).
We propose a collaborative clinical study in which Treg therapy for GHVD is the common dominator. However, by bringing together several clinical centers with expertise in this area, we are also having the opportunity to simultaneously address other issues that would not otherwise be addressable by each clinical center on its own. Firstly, by using different Treg preparation strategies, we will be able to determine whether ex vivo isolated Treg are sufficient or whether in vitro expansion and subsequently higher dosages are required. Secondly, we will investigate if sole Treg infusion is effective or if rather co-administration of therapeutic agents that are likely to induce Treg survival and expansion in vivo (rapamycin; IL-2) is required for a successful response to Treg therapy.
The studies on GVHD treatment outcome will be pursued together with a detailed analysis of immune monitoring, comprising T cell receptor clonotype tracking and tissue regeneration markers, in order to further understand the mechanisms underlying the therapeutic and regenerative potential of Treg cells.
Our consortium has developed a concerted approach to the topic of Treg therapy in GVHD. This is a unique opportunity to determine the validity of this cellular immunotherapy approach in GVHD prevention and treatment, with potential for a significant impact on patient quality of life, survival rate and ultimately on the quality of health care provided.
Contributo UE: EUR 1 547 895
AVENIDA PROF EGAS MONIZ
1649 028 LISBOA
Contributo UE: EUR 1 448 823,75
FRANS JOSEF STRAUSS ALLEE 11
Contributo UE: EUR 536 200
PLACE DU 20 AOUT 7
Contributo UE: EUR 767 500
VIA ALBERTONI 15
Contributo UE: EUR 741 335
Contributo UE: EUR 277 500
Contributo UE: EUR 246 077,50
BROWNLOW HILL 765 FOUNDATION BUILDING
L69 7ZX LIVERPOOL
Contributo UE: EUR 333 918,75
OSKAR VON MILLER RING 29